Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage
Objective: To assess the differences between two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: Opicapone and ENT are COMT inhibitors developed as adjunct…Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study
Objective: The objectives of this chart study were to evaluate adaptations in medication and flow rates and adverse events in patients with Parkinson’s disease (PD)…Levodopa-Entacapone-Carbidopa Intestinal Gel in the treatment of advanced Parkinson’s disease: a two-year experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in the treatment of patients with advanced Parkinson’s Disease (APD). Background: The continuous enteral infusion…Efficacy of levodopa/carbidopa/entacapone replacement of levodopa/dopa decarboxylase inhibitors in treatment of Chinese Parkinson’s disease patients with wearing-off: a multicenter, randomized controlled, open label study
Objective: This study aimed to investigate the efficacy and safety comparison between LCE and Pramexol in Chinese PD patients with the wearing-off phenomenon. Background: Wearing…Impact of oral COMT-inhibitors on gut microbiota and biologically active microbial metabolites in patients with Parkinson’s Disease
Objective: To investigate if we were able to reproduce our previous findings in an independent patient cohort and whether such a correlation also exists in…Sustained release triple drug loaded Microbaloons for management of Parkinson’s Disease
Objective: It is hypothesized that a drug delivery system that provides controlled and sustained release of PD drugs would afford better management of PD. Hollow…A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone
Objective: ODM-104 is a novel non-nitrocatechol catechol-O-methyltransferase (COMT) inhibitor that is undergoing clinical evaluation for Parkinson’s disease (PD). This study investigated the pharmacodynamic effects of…Post-hoc analyses of the recommended starting dose for Rytary based on “off” time
Objective: To determine whether correcting for “off” time duration improves the selection of the final LD dose when converting to extended-release carbidopa-levodopa capsules (ER CD-LD,…Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study
Objective: To compare the systemic levodopa exposure during administration of levodopa-entacapone-carbidopa (LECIG) intestinal gel with levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson's disease (PD) patients.…Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.